Proteomic Analysis Revealed Underlying Biological Pathways Associated with Hormetic Response of Hormone- Positive Breast Cancer Cell Line Exposed to Low-Dose Flavonoid Mixture

Abstract

Objective: A considerable level of evidence has accumulated about the breast cancer risk-reducing effect of consuming specific flavonoids, through the increasing amount of research and epidemiologic studies. Different flavonoids may have different cellular bioavailability and favor, i.e., the occurrence of a hormetic effect, thus it is important to evaluate breast cancer cells’ response to different doses of flavonoids. This study aims to investigate the alterations of the biological pathways in a hormone-positive (HR+) breast cancer cell line as a resemblance for the most common breast cancer subtype, related to the low-dose exposure of the flavonoids.

Materials and Methods: Different levels of doses were applied to MCF-7 breast cancer cells. In order to determine cellular proliferation, WST-1 analysis was conducted. The highest proliferation was observed with cell lines exposed to a low-dose flavonoid mixture and these were selected for further analysis. Intracellular protein expression were investigated by peptide analysis on a nano LC-MS/MS platform. A protein-protein interaction network and pathway analysis were conducted for the proteins expressed differently between the groups.

Results: A total of 214 proteins were identified and 36 proteins with significant alterations (≥1.2-fold change, p≤0.05) were detected. Significant changes were observed in the pathways related to carbon metabolism, amino acid biosynthesis, splicing mechanism, mitochondrial protein import and translation elongation pathways.

Conclusion: Our study demonstrated that flavonoids can have a hormetic effect which can initially alter metabolic pathways vital for cell proliferation and survival. These pathways may include potential targets for enhancing the anticancer activity of the flavonoids.

Keywords

• Flavonoids
• breast cancer
• hormesis
• proteomics

References

1. 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-49.
2. 2. Rodríguez-García C, Sánchez-Quesada C, J Gaforio J. Dietary Flavonoids as Cancer Chemopreventive Agents: An Updated Review of Human Studies. Antioxidants 2019; 8(5): 137.
3. 3. Toreti VC, Sato HH, Pastore GM, Park YK, Recent progress of propolis for its biological and chemical compositions and its botanical origin, Evid Based Complement Alternat Med 2013; 697390.
4. 4. Banskota AH, Tezuka Y, Kadota S. Recent progress in pharmacological research of propolis. Phytother Res 2001; 15(7): 561-71.
5. 5. Peeters PH, Keinan-Boker L, van der Schouw YT, Grobbee DE. Phytoestrogens and breast cancer risk: Review of the epidemiological evidence. Breast Cancer Res Treat 2003; 77: 171-83.
6. 6. Lim DW, Giannakeas V, Narod SA. Survival Differences in Chinese Versus White Women With Breast Cancer in the United States: A SEER-Based Analysis. JCO Glob Oncol 2020; 6: 1582-92.
7. 7. Rupasinghe HP, Ronalds CM, Rathgeber B, Robinson RA. Absorption and tissue distribution of dietary quercetin and quercetin glycosides of apple skin in broiler chickens. J Sci Food Agric 2010; 90(7): 1172-8.
8. 8. Gonzales GB, Smagghe G, Grootaert C, Zotti M, Raes K, Van Camp J. Flavonoid interactions during digestion, absorption, distribution and metabolism: a sequential structure-activity/property relationship- based approach in the study of bioavailability and bioactivity. Drug Metab Rev 2015; 47(2): 175-90.

9. 9. Seyhan MF, Yılmaz E, Timirci-Kahraman Ö, Saygılı N, Kısakesen Hİ, Gazioğlu S, et al. Different propolis samples, phenolic content, and breast cancer cell lines: Variable cytotoxicity ranging from ineffective to potent. IUBMB Life 2019; 71(5): 619-31.
10. 10. Bonofiglio D, Giordano C, De Amicis F, Lanzino M, Andò S. Natural Products as Promising Antitumoral Agents in Breast Cancer: Mechanisms of Action and Molecular Targets. Mini Rev Med Chem 2016; 16(8): 596-604.
11. 11. Pal S, Konkimalla VB. Hormetic Potential of Sulforaphane (SFN) in Switching Cells’ Fate Towards Survival or Death. Mini Rev Med Chem 2016; 16(12): 980-95.
12. 12. Son TG, Camandola S, Mattson MP. Hormetic dietary phytochemicals. Neuromolecular Med 2008; 10(4): 236-46.
13. 13. Jodynis-Liebert J, Kujawska M. Biphasic Dose-Response Induced by Phytochemicals: Experimental Evidence. Journal of Clinical Medicine 2020; 9(3): 718.
14. 14. Narter F, Diren A, Kafkasli A, Eronat AP, Seyhan MF, Yilmaz-Aydogan H, et al. Anatolian Propolis Prevents Oxalate Kidney Stones: Dramatic Reduction of Crystal Deposition in Ethylene-Glycol-Induced Rat Model. Rec Nat Prod 2018; 12(5): 445-59.
15. 15. Huang KT, Chen YH, Walker AM. Inaccuracies in MTS assays: major distorting effects of medium, serum albumin, and fatty acids. Biotechniques 2004 Sep; 37(3): 406, 408, 410-2.
16. 16. Wiśniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods 2009; 6(5): 359-62.
17. 17. Akgun E, Tuzuner MB, Sahin B, Kilercik M, Kulah C, Cakiroglu HN, et al. Proteins associated with neutrophil degranulation are upregulated in nasopharyngeal swabs from SARS-CoV-2 patients. PLoS One 2020; 15(10): e0240012
18. 18. Carbon S, Ireland A, Mungall CJ, Shu S, Marshall B, Lewis S, AmiGO Hub; Web Presence Working Group. AmiGO: online access to ontology and annotation data. Bioinformatics 2009; 25(2): 288-9.
19. 19. Batra P, Sharma AK. Anti-cancer potential of flavonoids: recent trends and future perspectives. 3 Biotech 2013; 3(6): 439-59.
20. 20. Coller HA. Is cancer a metabolic disease? Am J Pathol 2014; 184(1): 4-17.
21. 21. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab 2016; 23(1): 27-47.
22. 22. Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci 2016; 41(3): 211-8.
23. 23. Richardson AD, Yang C, Osterman A, Smith JW. Central carbon metabolism in the progression of mammary carcinoma. Breast Cancer Res Treat 2008; 110(2): 297-307.
24. 24. Samec M, Liskova A, Koklesova L, Samuel SM, Zhai K, Buhrmann C, et al. Flavonoids against the Warburg phenotype-concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism. EPMA J 2020; 11(3): 377-98.
25. 25. Zang HY, Gong LG, Li SY, Hao JG. Inhibition of α-enolase affects the biological activity of breast cancer cells by attenuating PI3K/Akt signaling pathway. Eur Rev Med Pharmacol Sci 2020; 24(1): 249-57.
26. 26. Locasale JW. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer 2013; 13: 572-83.
27. 27. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011; 476(7360): 346-50.
28. 28. Liu C, Wang L, Liu X, Tan Y, Tao L, Xiao Y, et al. Cytoplasmic SHMT2 drives the progression and metastasis of colorectal cancer by inhibiting β-catenin degradation. Theranostics 2021; 11(6): 2966-86.
29. 29. Maniatis T, Reed R. An extensive network of coupling among gene expression machines. Nature 2002; 416: 499-506.
30. 30. Millevoi S, Vagner S. Molecular mechanisms of eukaryotic pre-mRNA 3’ end processing regulation. Nucleic Acids Res 2009; 38: 2757- 74.
31. 31. Orphanides G, Reinberg D. A unified theory of gene expression. Cell 2002; 108: 439-51.
32. 32. Scotti MM, Swanson MS. RNA mis-splicing in disease. Nat Rev Genet 2016; 17(1): 19-32.
33. 33. Kurata M, Fujiwara N, Fujita KI, Yamanaka Y, Seno S, Kobayashi H, et al. Food-Derived Compounds Apigenin and Luteolin Modulate mRNA Splicing of Introns with Weak Splice Sites. iScience 2019; 22: 336-52.
34. 34. Geuens T, Bouhy D, Timmerman V. The hnRNP family: insights into their role in health and disease. Hum Genet 2016; 135(8): 851-67.
35. 35. Silipo M, Gautrey H, Tyson-Capper A. Deregulation of splicing factors and breast cancer development. J Mol Cell Biol 2015; 7(5): 388- 401.
36. 36. Calderwood SK, Gong J. Heat Shock Proteins Promote Cancer: It’s a Protection Racket. Trends Biochem Sci 2016; 41(4): 311-23.
37. 37. Hosokawa N, Hirayoshi K, Nakai A, Hosokawa Y, Marui N, Yoshida M, et al. Flavonoids inhibit the expression of heat shock proteins. Cell Struct Funct 1990; 15(6): 393-401.
38. 38. Wadhwa R, Yaguchi T, Hasan MK, Mitsui Y, Reddel RR, Kaul SC. Hsp70 family member, mot-2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein. Exp Cell Res 2002; 274(2): 246-53.
39. 39. Wadhwa R, Takano S, Kaur K, Deocaris CC, Pereira-Smith OM, Reddel RR, et al. Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int J Cancer 2006; 118(12): 2973-80.
40. 40. Na Y, Kaul SC, Ryu J, Lee JS, Ahn HM, Kaul Z et al. Stress chaperone mortalin contributes to epithelial-mesenchymal transition and cancer metastasis. Cancer Res 2016; 76(9): 2754-65.
41. 41. Zhang R, Meng Z, Wu X, Zhang M, Zhang S, Jin T. Mortalin promotes breast cancer malignancy. Exp Mol Pathol 2021;118:104593.
42. 42. Huang TC, Chang HY, Hsu CH, Kuo WH, Chang KJ, Juan HF. Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin B. J Proteome Res 2008; 7: 1433-44.
43. 43. Pan J, Sun LC, Tao YF, Zhou Z, Du XL, Peng L, et al. ATP synthase ecto-alpha subunit: a novel therapeutic target for breast cancer. J Transl Med 2011; 9: 211.
44. 44. Isidoro A, Casado E, Redondo A, Acebo P, Espinosa E, Alonso AM, et al. Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis 2005; 26: 2095-104.
45. 45. Willers IM, Cuezva JM. Post-transcriptional regulation of the mitochondrial H(+)-ATP synthase: a key regulator of the metabolic phenotype in cancer. Biochim Biophys Acta 2011; 1807: 543-51.
46. 46. Cuezva JM, Krajewska M, de Heredia ML, Krajewski S, Santamaría G, Kim H, et al. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 2002; 62: 6674-81.
47. 47. Zheng SQ, Li YX, Zhang Y, Li X, Tang H. MiR-101 regulates HSV-1 replication by targeting ATP5B. Antiviral Res 2011; 89: 219-26.
48. 48. Bilanges B, Stokoe D. Mechanism of translational deregulation in human tumors and therapeutic intervention strategies. Oncogene 2007; 26: 5973-90.
49. 49. Hassan MK, Kumar D, Naik M, Dixit M. The expression profile and prognostic significance of eukaryotic translation elongation factors in different cancers. PLoS One 2018; 13(1): e0191377.
50. 50. Meric-Bernstam F, Chen H, Akcakanat A, Do KA, Lluch A, Hennessy BT, Hortobagyi GN, Mills GB, et al. Aberrations in translational regulation are associated with poor prognosis in hormone receptor- positive breast cancer. Breast Cancer Res 2012; 14: R138.
51. 51. Yao N, Chen CY, Wu CY, Motonishi K, Kung HJ, Lam KS. Novel flavonoids with antiproliferative activities against breast cancer cells. J Med Chem 2011; 54(13): 4339-49.
52. 52. Xu L, Wang L, Jiang C, Zhu Q, Chen R, Wang J, et al. Biological effect of ribosomal protein L32 on human breast cancer cell behavior. Mol Med Rep 2020; 22(3): 2478-86.